CLOSE

The pressure to develop a coronavirus vaccine is increasing every day, but some time is needed for a safe vaccine to enter the market.

USA TODAY

The US announced on Friday that it will pay the French pharmaceutical company Sanofi and the United Kingdom GlaxoSmithKline up to $ 2.1 billion for testing and producing 100 million doses of experimental coronavirus vaccine.

More than half of the money will support further development and early clinical trials to ensure that they are safe and effective. The rest will be paid for the first 100 million benefits with the possibility of another 500 million.

Most of the $ 2.1 billion will go to Sanofi, making it a vaccine candidate. GlaxoSmithKline has created a booster that improves the body’s response to it.

The agreement is part of Operation Warp Speed, a White House-led initiative to get a vaccine to stop SARS-CoV-2, the virus that causes COVID-19. The Trump Administration initiative has now spent more than $ 8 billion on experimental vaccines that may or may not get across the finish line.

“Historical moment: Extensive studies are being initiated with potential COVID-19 vaccines

Operation Warp Speed: Officials avert criticism, saying “we are taking all possible steps” for the safe COVID-19 vaccine

Expert panel: Early success of COVID-19 vaccine candidates encourages optimism, but experts warn that “a lot must go right”

They are made “at risk” – before they are licensed. If any of the vaccines are not approved, the accumulated doses will be destroyed.

The companies are working with the US Department of Health and Human Services and the Department of Defense to increase their manufacturing capacity in the United States.

The Sanofi experimental vaccine uses DNA and the never-released experimental vaccine against SARS. Phase 1 and Phase 2 vaccine candidate clinical trials will begin in September, said Thomas Triomphe, global head of Sanofi Pasteur, Sanofi’s vaccine wing.

The potential vaccine could begin phase 3 studies, the final pre-licensing phase, by the end of 2020. If it proves safe and effective, companies expect to seek regulatory approval in the first half of 2021.

This is the fourth agreement in which the federal government has committed to buy benefits if companies develop successful coronavirus vaccines.

CLOSE

Anthony Fauci said the development of the coronavirus vaccine was moving at a high rate on Tuesday. Fauci made a statement by President Donald Trump, who on Tuesday declared a harsh defense against the misuse of the drug malaria as a treatment.e coronavirus. (July 28)

AP Home

According to an agreement reached in May, the British-Swedish company AstraZeneca will receive $ 1.2 billion for 300 million benefits. An agreement with US-based Pfizer was announced in July for $ 1.95 billion for 100 million benefits. Maryland-based Novavax announced in July that it will receive $ 1.6 billion from the government to fund the development, testing and 100 million doses of its vaccine candidate.

“The portfolio of vaccines being prepared for Operation Warp Speed ​​increases the likelihood that we will have at least one safe and effective vaccine soon at the end of this year,” Health and Human Services Minister Alex Azar said in a written statement.

The latest agreement has “the potential to bring hundreds of millions of safe and effective benefits to the American people,” he said.

Sanofi and GSK said they have committed to making the vaccine available worldwide and are building production capacity to produce up to 1 billion doses per year.

A DNA vaccine candidate is one of two companies they are working on. The second is the messenger RNA vaccine, the same type developed by modernity.

As for the second, they anticipate starting phase 1 testing by the end of 2020 and plan to have the vaccine ready for regulatory approval in the second half of 2021, the companies said.

Read or share this story: https://www.usatoday.com/story/news/2020/07/31/2-1-billion-sanofi-gsk-deal-100-million-coronavirus-vaccine-doses/5554814002 /